Rafi Ahmed

Emory University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Supplementary Table 2: Antibodies used for immune-phenotyping (CyTOF analysis). Supplementary Table 3: Antibodies used for flow cytometry. Supplementary Table 4: Antibodies used for AIM Assay (CyTOF analysis).

Year:

2025

PURPOSE To examine COVID-19 mRNA vaccine–induced binding and neutralizing antibody responses in patients with non–small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose and booster vaccination. METHODS Eighty-two patients with NSCLC and 53 healthy volunteers who received SARS-CoV-2 mRNA vaccines were included in the study. Blood was collected longitudinally, and SARS-CoV-2–specific binding and neutralizing antibody responses were evaluated by Meso Scale Discovery assay and live virus Focus Reduction Neutralization Assay, respectively. RESULTS A majority of patients with NSCLC generated binding and neutralizing antibody titers comparable with the healthy vaccinees after mRNA vaccination, but a subset of patients with NSCLC (25%) made poor responses, resulting in overall lower (six- to seven-fold) titers compared with the healthy cohort ( P = < .0001). Although patients age > 70 years had lower immunoglobulin G titers ( P = < .01), patients receiving programmed death-1 monotherapy, chemotherapy, or a combination of both did not have a significant impact on the antibody response. Neutralizing antibody titers to the B.1.617.2 (Delta), B.1.351 (Beta), and in particular, B.1.1.529 (Omicron) variants were significantly lower ( P = < .0001) compared with the 614D (WT) strain. Booster vaccination led to a significant increase ( P = .0001) in the binding and neutralizing antibody titers to the WT and Omicron variant. However, 2-4 months after the booster, we observed a five- to seven-fold decrease in neutralizing titers to WT and Omicron viruses. CONCLUSION A subset of patients with NSCLC responded poorly to the SARS-CoV-2 mRNA vaccination and had low neutralizing antibodies to the B.1.1.529 Omicron variant. Booster vaccination increased binding and neutralizing antibody titers to Omicron, but antibody titers declined after 3 months. These data highlight the concern for patients with cancer given the rapid spread of SARS-CoV-2 Omicron variant.

Year:

2022

Collaborators (15)

Jonathan Kaufman

Winship Cancer Institute of Emory University

UNITED STATES
View details

Alberto Moreno

Emory University

UNITED STATES
View details

Renee Julia Manalo

Emory University

UNITED STATES
View details

Margaret Johns

Winship Cancer Institute of Emory University

UNITED STATES
View details

Kelly Manning

Staff Scientist

Emory University

UNITED STATES
View details

Mehul S. Suthar

Emory University School of Medicine

UNITED STATES
View details

Sagar Lonial

-

UNITED STATES
View details

Craig Hofmeister

Professor

Emory University

UNITED STATES
View details

Rafi Ahmed

Emory University School of Medicine

UNITED STATES
View details

Ajay K. Nooka

Professor

Emory University

UNITED STATES
View details

Nisha Joseph

Associate Professor

Winship Cancer Institute of Emory University

UNITED STATES
View details

Madhav V. Dhodapkar

-

UNITED STATES
View details

Alessandro Sette

Professor and Member

La Jolla Institute for Immunology

UNITED STATES
View details

Kavita M. Dhodapkar

Emory University

UNITED STATES
View details

Jeffrey Switchenko

Emory University

UNITED STATES
View details